Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma

References

• Cancer of the kidney and renal pelvis - cancer stat facts. SEER., Available from: https://seer.cancer.gov/statfacts/html/kidrp.html. Available from: 2019 Dec 24
   Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(p):17009.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212528.
   PubMedGoogle Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Michaelson MD, et al. NCCN guidelines insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw. 2019;17(11):1278–1285.
   PubMed Web of Science ®Google Scholar
• Albiges L, Powles T, Staehler M, et al. Updated European Association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151–156.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2020;31:S1159.
   Web of Science ®Google Scholar
• ESMO, eUpdate e renal cell carcinoma treatment recommendations. Available at: https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations-3. 2020 Nov 30
   Google Scholar
• Bedke J, Albiges L. Capitanio U, et al. Updated European Association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. European Urology. 2021;79(3):339-342.
   Google Scholar
• News release Merck, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) demonstrated statistically significant improvement in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma. Available from: Nov 10, 2020. https://bit.ly/38yQ3o7.
   Google Scholar
• Jubb AM, Pham TQ, Hanby AM, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004;57(5):504–12.
   PubMed Web of Science ®Google Scholar
• Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–324.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Motz GT, Busch J, et al. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol. 2011;344:129–148.
   PubMed Web of Science ®Google Scholar
• Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726–4734.
   PubMed Web of Science ®Google Scholar
• Barry RE, Krek W. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med. 2004;10(9):466–472.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117–124.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
   PubMed Web of Science ®Google Scholar
• Siska PJ, Beckermann KE, Mason FM, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight. 2017;2(12):e93411.
   Web of Science ®Google Scholar
• Giraldo NA, Becht E, Pages F, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031–3040.
   PubMed Web of Science ®Google Scholar
• Huang H, Langenkamp E, Georganaki M, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. Faseb J. 2015;29(1):227–238.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Damen CA, Martinotti S, et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996;56(5):1111–1117.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615.
   PubMed Web of Science ®Google Scholar
• Pittet CL, Newcombe J, Prat A, et al. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation. 2011;8(1):155.
   PubMed Web of Science ®Google Scholar
• Seaman S, Stevens J, Yang MY, et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11(6):539–554.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728–5739.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007;110(2):624–631.
   PubMed Web of Science ®Google Scholar
• Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008;57(8):1115–1124.
   PubMed Web of Science ®Google Scholar
• Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100(7):1111–1119.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096–1103.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562–567.
   PubMed Web of Science ®Google Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878–4886.
   PubMed Web of Science ®Google Scholar
• Gavalas NG, Tsiatas M, Tsitsilonis O, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer. 2012;107(11):1869–1875.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148.
   PubMed Web of Science ®Google Scholar
• Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139(2):396–403.
   PubMed Web of Science ®Google Scholar
• Manning EA, Ullman JG, Leatherman JM, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007;13(13):3951–3959.
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171–6180.
   PubMed Web of Science ®Google Scholar
• Elamin YY, Rafee S, Toomey S, et al. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2015;8(1):15–21.
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Nijman HW, Hoogeboom BN, et al. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology. 2015;4(3):e989764.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561–17566.
   PubMed Web of Science ®Google Scholar
• Henze A-T, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 2016;126(10):3672–3679.
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Eruslanov E, Kübler H, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181(1):346–353.
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12(1):294.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513.
   PubMed Web of Science ®Google Scholar
• Ko JJ, Xie W, Kroeger N, et al. The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293–300.
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573.
   PubMed Web of Science ®Google Scholar
• Bedke J, Rini B, Plimack E, et al. Health-related quality-of-life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC). 35th Annual EAU Congress - Virtual (EAU20V); 2020.
   Google Scholar
• Soulières D, Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma: subgroup analysis from KEYNOTE-426 by prior nephrectomy. Presented at IKCS 2020: A Virtual Experience; 2020 Nov 6-7, 2020.
   Google Scholar
• Atkins MB, Puzanov I, Plimack ER, et al. Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: long-term efficacy and safety from a phase Ib study. J clin oncol. 2020;38(15_suppl): 5080-5080. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.5080
   Google Scholar
• Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039.
   PubMed Web of Science ®Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415.
   PubMed Web of Science ®Google Scholar
• Pal S, Tsao CK, E.a. Suarez C, Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from the COSMIC-021 study. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract 702O.
   Google Scholar
• ClinicalTrials.gov, A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03). Available from: https://clinicaltrials.gov/ct2/show/NCT04338269, Available from: 2020 Dec 12
   Google Scholar
• Taylor MH, Lee C-H, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–1163.
   PubMed Web of Science ®Google Scholar
• Lee C-H, Shah AY, Hsieh JJ, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J clin oncol. 2020;38(15_suppl): 5008-5008. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.5008
   Google Scholar
• Motzer RJ, Grünwald V, Hutson TE, et al. A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma. J clin oncol. 2018;36(6_suppl): TPS706-TPS706.
   Web of Science ®Google Scholar
• Escudier B, Barthelemy P, Ravaud A, et al. Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J clin oncol. 2018;36(6_suppl): 618-618. DOI:https://doi.org/10.1200/JCO.2018.36.6_suppl.618
   Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J clin oncol. 2014;32(15_suppl): 5010-5010. DOI:https://doi.org/10.1200/jco.2014.32.15_suppl.5010
   Google Scholar
• Chowdhury S, McDermott DF, Voss MH, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J clin oncol. 2017;35(15_suppl): 4506-4506. DOI:https://doi.org/10.1200/JCO.2017.35.15_suppl.4506
   Google Scholar
• Keeler ME, Kessler ER, Bernard B, et al. Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): phase I results. J clin oncol. 2019;37(7_suppl): 600-600. DOI:https://doi.org/10.1200/JCO.2019.37.7_suppl.600
   Google Scholar
• Apolo AB, Nadal R, Girardi DM, et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J clin oncol. 2020;38(31):3672–3684.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Albiges L, Powles T, et al. A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk. J clin oncol. 2020;38(6_suppl): TPS767-TPS767.
   Web of Science ®Google Scholar
• Zhang T, Ballman KV, Choudhury AD, et al. PDIGREE: an adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). J clin oncol. 2019;37(15_suppl): TPS4596-TPS4596.
   Google Scholar
• Hirsch L, Flippot R, Escudier B, et al. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. 2020;80(12):1169–1181.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174.
   PubMed Web of Science ®Google Scholar
• Tannir NM, McDermott DF, Escudier B, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J clin oncol. 2020;38(6_suppl): 609-609. DOI:https://doi.org/10.1200/JCO.2020.38.6_suppl.609
   Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020;8(2):e000891.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. -
   PubMed Web of Science ®Google Scholar
• Läubli H, Müller P, D’Amico L, et al. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunol Immunother. 2018;67(5):815–824.
   PubMed Web of Science ®Google Scholar
• Drake CG, Stein MN. The immunobiology of kidney cancer. J clin oncol. 2018;36(36):3547–3552.
   Web of Science ®Google Scholar
• Aeppli S, Schmaus M, Eisen T, et al. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open. 2021;6(1):100030.
   Web of Science ®Google Scholar
• Albiges L, Tannir N, Burotto M, et al. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. Ann Oncol. 2020;31:S559–S560.
   Web of Science ®Google Scholar
• McDermott DF, Choueiri TK, Motzer RJ, et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J clin oncol. 2019;37(15_suppl): 4513-4513. DOI:https://doi.org/10.1200/JCO.2019.37.15_suppl.4513
   Google Scholar
• McDermott DF, Lee J-L, Bjarnason GA, et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. J clin oncol. 2020;38(15_suppl): 5069-5069. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.5069
   Google Scholar
• Lee J-L, Ziobro M, Suarez C, et al. First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): updated follow-up for KEYNOTE-427 cohort B. J clin oncol. 2020;38(15_suppl): 5034-5034. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.5034
   Google Scholar
• Motzer RJ, Tykodi SS, Escudier B, et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). J clin oncol. 2020;38(6_suppl): 617-617. DOI:https://doi.org/10.1200/JCO.2020.38.6_suppl.617
   Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J clin oncol. 2019;37(15_suppl): 4500-4500. DOI:https://doi.org/10.1200/JCO.2019.37.15_suppl.4500
   Google Scholar
• Rini BI, ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis - Medical Oncologist Perspective Presented by: Brian I. Rini, Medical Oncologist, Cleveland Clinic, Cleveland, OH; Written by: Thenappan Chandrasekar, MD, Clinical Instructor, Thomas Jefferson University, @tchandra_uromd, @JEFFUrology, at the 2019 ASCO Annual Meeting #ASCO19, May 31-June 4, 2019, Chicago, IL USA, 2019.
   Google Scholar
• Choueiri TK, Larkin JMG, Pal SK, et al. Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S). Ann Oncol. 2019;30(suppl_5):v356–v402.
   Google Scholar
• Su Y, Fu J, Du J, et al. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. Ther Adv Med Oncol. 2020;12:1758835920950199.
   Web of Science ®Google Scholar
• Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108:33–40.
   PubMed Web of Science ®Google Scholar
• Ged Y, Gupta R, Duzgol C, et al. Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF). J clin oncol. 2019;37(15_suppl): 4576-4576. DOI:https://doi.org/10.1200/JCO.2019.37.15_suppl.4576
   Google Scholar
• Lee C, Shah AY, Makker V, et al. 4181 - Phase 2 study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an interim analysis. Ann Oncol. 2019;30(suppl_5):v475–v532.
   Google Scholar
• Grimm M-O, Schmidinger M, Duran Martinez I, et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC). Ann Oncol. 2019;30:v892.
   Web of Science ®Google Scholar
• Choueiri TK, Kluger HM, George S, et al. FRACTION-RCC: innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). J clin oncol. 2020;38(15_suppl): 5007-5007. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.5007
   Google Scholar
• McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757.
   PubMed Web of Science ®Google Scholar
• Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–918.
   PubMed Web of Science ®Google Scholar
• Carretero-González A, Lora D, Martín Sobrino I, et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel). 2020;12(7):1945.
   PubMed Web of Science ®Google Scholar
• Rini BI, Huseni M, Atkins MB, et al. Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). . Annals of Oncology. 2018;29(Suppl. 8):LBA31.
   Google Scholar
• Şenbabaoğlu Y, Gejman RS, Winer AG, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17(1):231.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Albiges L, Haanen JBAG, et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J clin oncol. 2019;37(15_suppl): 101-101. DOI:https://doi.org/10.1200/JCO.2019.37.15_suppl.101
   Google Scholar
• Epaillard N, Simonaggio A, Elaidi R, et al. BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin Du Cancer. 2020;107(5):eS22–eS27.
   PubMed Web of Science ®Google Scholar
• Vano Y, Elaidi R, B.M. et al. Results from the phase 2 BIOmarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial (NCT02960906). Presented at: 2020 ESMO Congress; 2020 Sept 19-21; Virtual. Abstract: LBA25., 2020.
   Google Scholar